Muse Stem Cells Explained: What Patients Should Know About This Pluripotent Cell Therapy
Written by Dr. David Greene, MD, PhD, MBA on March 11, 2026
If you’ve been researching stem cell therapies, you may have come across a term that’s gaining attention in regenerative medicine: Muse cells. Short for Multilineage-Differentiating Stress-Enduring cells, Muse cells represent an exciting frontier in cell-based therapy — one that bridges the gap between the broad versatility of pluripotent stem cells and the established safety profile of mesenchymal stem cells.
This article explains what Muse cells are, how they differ from conventional stem cell therapies, what the current science shows, and what treatment options are available today.
Muse cells are a rare, naturally occurring subpopulation found within mesenchymal stem cells (MSCs). They were first identified in 2010 by Dr. Mari Dezawa and her research team at Tohoku University in Sendai, Japan. The discovery was significant because it revealed that a small fraction of ordinary mesenchymal tissue — including bone marrow, adipose (fat) tissue, and umbilical cord — contains cells with properties far beyond what typical MSCs can achieve.
In a standard preparation of umbilical cord mesenchymal stem cells, only about 1–3% are Muse cells. To isolate them for therapeutic use, researchers use cell-sorting techniques that identify Muse cells based on a specific surface marker called SSEA-3 (Stage-Specific Embryonic Antigen-3).
According to peer-reviewed literature, Muse cells can be isolated from dermal fibroblasts, bone marrow, adipose tissue, and umbilical cord tissue using fluorescence-activated cell sorting (FACS) or by exposing cell cultures to severe stress conditions, which Muse cells are uniquely equipped to survive — hence their name [3].
One of the most important distinctions for patients to understand is where Muse cells fall on the stem cell spectrum.
Mesenchymal stem cells (MSCs) are classified as multipotent, meaning they can differentiate into a limited range of related cell types — primarily bone, cartilage, and fat cells. They are widely used in regenerative medicine and have a well-documented safety profile.
Pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), can differentiate into virtually any cell type in the body. However, they carry well-known risks: the potential to form tumors (teratomas) and immune rejection.
Muse cells occupy a unique position between these two categories. Published research describes them as having pluripotent-like characteristics — they can spontaneously differentiate into cells representative of all three embryonic germ layers (ectoderm, mesoderm, and endoderm) — while maintaining key safety advantages [2]:
One of the most clinically relevant properties of Muse cells is their ability to home to areas of injury after intravenous administration. This is the same principle observed with standard mesenchymal stem cells, which have been shown in research to migrate toward sites of inflammation and tissue damage when delivered through the bloodstream.
Muse cells appear to accomplish this homing through a specific biological pathway. Damaged and inflamed tissues release a signaling molecule called sphingosine-1-phosphate (S1P). Muse cells express the receptor S1PR2 on their surface, which allows them to detect and preferentially migrate toward areas producing S1P. This S1P–S1PR2 axis is considered a primary mechanism through which Muse cells locate and reach injured tissues after IV infusion [4].
This targeted homing capability is a key reason why Muse cell therapy is typically administered intravenously — the cells enter the bloodstream and are guided to the areas where they are most needed.
The body of evidence on Muse cells has been growing steadily since their discovery. According to published reviews in PubMed, preclinical (animal model) studies have demonstrated regenerative effects in a range of conditions, including stroke, intracerebral hemorrhage, acute myocardial infarction, liver fibrosis, kidney disease (focal segmental glomerulosclerosis), skin ulcers, and lung injuries [1]
In Japan, clinical trials have moved forward to evaluate intravenous Muse cell therapy (a product designated CL2020, developed by Life Science Institute, Inc.) in human patients. Conditions studied in clinical trials include:
It is important for patients to understand that while these early-phase clinical trials have shown encouraging safety and efficacy signals, Muse cell therapy is still considered investigational. Large-scale,
randomized controlled trials are needed to establish definitive clinical efficacy and optimal treatment protocols. The research is promising, but it is still evolving.
Because Muse cells are isolated from mesenchymal tissue sources using specialized cell-sorting techniques, the preparation process is more involved than standard MSC therapy. The cells are identified by their SSEA-3 surface marker and separated from the broader MSC population.
At R3 Stem Cell, Muse cell therapy is offered as an intravenous (IV) infusion. Due to their enhanced potency compared to unselected mesenchymal stem cells, treatment typically involves lower cell counts — commonly in the range of 20 to 40 million cells — compared to the 50–150 million cells used in standard umbilical cord MSC IV protocols.
For patients who require both systemic (IV) and localized treatments, R3 Stem Cell uses a staged approach. Muse cells are administered intravenously first to take advantage of the homing mechanism. Then, approximately 48 hours later, additional treatments using standard umbilical cord mesenchymal stem cells can be delivered through localized routes such as:
The two-day interval between treatments is designed to allow the Muse cells adequate time to circulate, detect signals from damaged tissues, and begin the homing process before introducing additional cell therapies
Both Muse cells and standard umbilical cord MSCs have roles in regenerative medicine. The choice between them — or whether to combine them — depends on the individual patient’s condition and treatment goals.
| Feature | Umbilical Cord MSCs | Muse Cells |
| Differentiation potential | Multipotent (bone, cartilage, fat) | Pluripotent-like (all three germ layers) |
| Proportion in MSC cultures | ~97–99% of population | ~1–3% of population |
| Tumor risk | Very low | Not observed in studies |
| Immune rejection risk | Low | Very low (inherent immune privilege) |
| Homing ability | Present | Enhanced (via S1P-S1PR2 axis) |
| Typical IV dose | 50–150 million cells | 20–40 million cells |
| Clinical evidence | Extensive preclinical and clinical data | Growing body of preclinical and early clinical data |
| Delivery routes | IV, injection, nebulizer, intranasal, intrathecal | Primarily IV |
For many patients, standard umbilical cord MSC therapy remains an effective and well-supported option. Muse cells may offer additional advantages for patients with systemic conditions where enhanced tissue homing and broader differentiation capacity could be beneficial.
R3 Stem Cell offers both Muse cell therapy and standard umbilical cord mesenchymal stem cell therapy at its clinics in Tijuana, Cancún, and Puerto Vallarta, Mexico. As the global leader in regenerative therapies with over 27,000 procedures performed, R3 Stem Cell provides patients with access to advanced cell-based treatments under experienced medical oversight.
Patients considering Muse cell therapy or conventional MSC treatments can schedule a free consultation to discuss their condition, treatment options, and whether a standalone or hybrid protocol may be appropriate for their needs.
Muse cells represent a meaningful advancement in regenerative medicine — a naturally occurring stem cell type that combines pluripotent-like versatility with the safety profile that has made mesenchymal stem cells a cornerstone of cell-based therapy. The research, while still maturing, provides a compelling scientific foundation for their use in treating a range of conditions.
As with any medical treatment, patients should consult with qualified healthcare providers, review the available evidence, and make informed decisions about their care. The field of regenerative medicine is advancing rapidly, and Muse cells are one of the most promising developments to emerge in recent years.
This article is for educational purposes only and does not constitute medical advice. Stem cell treatments, including Muse cell therapy, are considered investigational and have not been approved by the FDA for most indications. Results vary by patient. Consult with a qualified healthcare provider before pursuing any treatment.
References:
Contact Us